文献速递前列腺癌

双参数前列腺MRI诊断前列腺癌准确性的系统综述与荟萃分析

A systematic review and meta-analysis of the diagnostic accuracy of biparametric prostate MRI for prostate cancer in men at risk.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2020-11-20

结果显示bpMRI检测任何前列腺癌的合并敏感度为0.84、特异度为0.75、AUC为0.86;检测临床显著前列腺癌的合并敏感度为0.87、特异度为0.72、AUC为0.87。荟萃回归分析未发现bpMRI与多参数MRI(mpMRI)的诊断估计值存在差异。

要点

  • bpMRI检测任何前列腺癌的合并敏感度0.84、特异度0.75、AUC 0.86。
  • bpMRI检测临床显著前列腺癌的合并敏感度0.87、特异度0.72、AUC 0.87。
  • 荟萃回归未发现bpMRI与mpMRI的诊断估计值存在差异。

核心结论

  • 当代研究的荟萃分析显示,bpMRI在检测前列腺癌方面提供的测试准确性与mpMRI相当。
  • 这些数据广泛支持bpMRI方法,但异质性不允许做出确定性推荐。
  • 需要对活检初治男性进行前瞻性多中心bpMRI研究。

研究设计与样本

  • 系统综述与荟萃分析,检索2017年1月1日至2019年6月7日的文献。
  • 由两名独立评价者使用预定义检索标准进行文献筛选。
  • 索引试验为双参数MRI,参考标准为全mount前列腺切除标本或前列腺活检。
  • 纳入研究质量采用QUADAS-2工具评估。
  • 统计分析包括合并诊断性能、可能协变量的荟萃回归以及同一研究内bpMRI与mpMRI的头对头比较。

主要发现

  • bpMRI检测任何前列腺癌的合并敏感度为0.84(95% CI,0.80-0.88),特异度为0.75(95% CI,0.68-0.81)。
  • 汇总ROC曲线得出高AUC值(AUC = 0.86)。
  • bpMRI检测临床显著前列腺癌的合并敏感度为0.87(95% CI,0.78-0.93),特异度为0.72(95% CI,0.56-0.84),AUC值为0.87。
  • 荟萃回归分析显示bpMRI与mpMRI的合并诊断估计值无差异。

临床怎么用

  • bpMRI可作为mpMRI的替代方案用于前列腺癌检测,但需注意研究异质性限制确定性推荐。
  • 在活检初治男性中应用bpMRI前,应等待前瞻性多中心研究进一步验证。

局限性

  • 研究间存在异质性,不允许做出确定性推荐。
  • 需要针对活检初治男性的前瞻性多中心研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Multiparametric magnetic resonance imaging (mpMRI), the use of three multiple imaging sequences, typically T2-weighted, diffusion weighted (DWI) and dynamic contrast enhanced (DCE) images, has a high sensitivity and specificity for detecting significant cancer. Current guidance now recommends its use prior to biopsy. However, the impact of DCE is currently under debate regarding test accuracy. Biparametric MRI (bpMRI), using only T2 and DWI has been proposed as a viable alternative. We conducted a contemporary systematic review and meta-analysis to further examine the diagnostic performance of bpMRI in the diagnosis of any and clinically significant prostate cancer. METHODS: A systematic review of the literature from 01/01/2017 to 06/07/2019 was performed by two independent reviewers using predefined search criteria. The index test was biparametric MRI and the reference standard whole-mount prostatectomy or prostate biopsy. Quality of included studies was assessed by the QUADAS-2 tool. Statistical analysis included pooled diagnostic performance (sensitivity; specificity; AUC), meta-regression of possible covariates and head-to-head comparisons of bpMRI and mpMRI where both were performed in the same study. RESULTS: Forty-four articles were included in the analysis. The pooled sensitivity for any cancer detection was 0.84 (95% CI, 0.80-0.88), specificity 0.75 (95% CI, 0.68-0.81) for bpMRI. The summary ROC curve yielded a high AUC value (AUC = 0.86). The pooled sensitivity for clinically significant prostate cancer was 0.87 (95% CI, 0.78-0.93), specificity 0.72 (95% CI, 0.56-0.84) and the AUC value was 0.87. Meta-regression analysis revealed no difference in the pooled diagnostic estimates between bpMRI and mpMRI. CONCLUSIONS: This meta-analysis on contemporary studies shows that bpMRI offers comparable test accuracies to mpMRI in detecting prostate cancer. These data are broadly supportive of the bpMRI approach but heterogeneity does not allow definitive recommendations to be made. There is a need for prospective multicentre studies of bpMRI in biopsy naïve men.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Bass EJ, Pantovic A, Connor M, et al. A systematic review and meta-analysis of the diagnostic accuracy of biparametric prostate MRI for prostate cancer in men at risk. Prostate Cancer Prostatic Dis. 2020. PMID: 33219368. doi:10.1038/s41391-020-00298-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。